Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 8 | Arthritis Research & Therapy

Fig. 8

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Fig. 8

Patient-reported outcomes for certolizumab pegol (CZP) intention-to-treat (ITT) and week-24 CZP completer populations. a Change from baseline in patient’s assessment of arthritic pain. b Change from baseline in patient’s global assessment of disease activity (PtGA). c Change from baseline in fatigue. d Change from baseline in short form-36 physical component summary (SF-36 PCS). For patients who withdrew at week 16, observed data from the week-12 visit was also included in the week-24 data (start of open-label extension). MMRM mixed model repeated measures

Back to article page